Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1, Open-Label, PET Study of T2310 & BPN14770

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04044781
Recruitment Status : Withdrawn (Change in Research Direction)
First Posted : August 5, 2019
Last Update Posted : January 10, 2022
Sponsor:
Information provided by (Responsible Party):
Tetra Discovery Partners

Brief Summary:
This is a sponsor initiated, single site, first-in-human study of an investigational imaging agent for quantifying the topographically specific concentrations of the phosphodiesterase enzyme Type 4D (PDE4D) with positron emission tomography (PET) using a selective radioligand, [11C]T2310. T2310 will be measured with imaging techniques to characterize plasma exposure levels versus regionally specific target engagement fractions for oral doses of BPN14770, an investigational new drug (IND) for modulating PDE4D. BPN14770 is under evaluation for the treatment of Fragile X syndrome and Alzheimer's disease.

Condition or disease Intervention/treatment Phase
To Determine Brain Target Occupancy of BPN14770 Drug: BPN14770, T2310 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of BPN14770
Actual Study Start Date : January 10, 2020
Actual Primary Completion Date : April 30, 2020
Actual Study Completion Date : May 30, 2020

Arm Intervention/treatment
Experimental: Test Group
Stage 1 safety assessments will be performed before and after the administration of a single, 185 MBq (5mCi) dose of T2310 in up to three healthy volunteers. Stage 2 will evaluate the relationship between plasma concentration of BPN14770, an investigational PDE4D modulator, and brain target occupancy in up to six healthy volunteers.
Drug: BPN14770, T2310
Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.




Primary Outcome Measures :
  1. Adverse Events [ Time Frame: 1-8 Days ]
    To assess the safety and tolerability of [11C]T2310 when administered alone and when co-administered with BPN14770

  2. Plasma Concentration [ Time Frame: 24 Hours ]
    To determine relationships between plasma concentrations of BPN14770 and the total volume of distribution of T2310 as a proxy for brain PDE4D occupancy by BPN14770 following single oral dosing regimens of BPN14770 over a 24 hour time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 1. Willing and able to provide written informed consent.
  • 2. Subjectively healthy
  • 3. Between 18 and 75 years, inclusive, but preference will be given to subjects who are less than 55 years old.
  • 4. The subject weighs at least 45 kg and has a body mass index between 18.0 and 32 kg/m2.
  • 5. Subjects should be willing to observe the following contraception requirements from Screening until 90 days after the final follow-up visit: Male subjects must be willing to inform female partners of their participation in the study and must agree to use adequate contraceptive methods (vasectomy performed at least 6 months prior to dosing BPN14770 or use at least one barrier method of birth control). Female subjects: Female subjects must be surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to dosing of BPN14770), at least two years post-menopausal, or willing to use one barrier plus a hormonal contraceptive method of contraception from initial screening until one month after taking the last dose of study drug

Exclusion Criteria:

  • 1. Known history or evidence of a clinically significant medical condition, disorder, or disease that, in the opinion of the investigator, would pose a risk to subject safety, proper completion of the procedures, or the integrity of the study.
  • 2. Clinical laboratory studies suggestive of a medically meaningful disease or condition that, in the opinion of the investigator, could pose a risk to subject safety, proper completion of the procedures, or the integrity of the study.
  • 3. Contraindication to MRI based on the standard MRI screening questionnaire at CBIC. Contraindications include ferromagnetic foreign bodies (e.g., shrapnel, ferromagnetic sheet metal fragments in the orbital area), certain implanted medical devices (e.g., older aneurysm clips, cardiac pacemakers), or claustrophobia.
  • 4. Unexpected findings on screening MRI that are indicative of an occult brain disease, or will potentially compromise subject safety or the scientific integrity of the study data.
  • 5. Previous exposure to ionizing radiation for research purposes, such that, in combination with the exposure from this study, their exposure to research associated radiation will be >50 mSv/year for the previous year.
  • 6. Subjects who are atopic, or have a known hypersensitivity to any component of the formulation of BPN14770 or to [11C]T2310 PET scan.
  • 7. History of substance dependence, or current use of drugs of abuse.
  • 8. History of regular weekly alcohol consumption >21 units for male subjects or >14units for female subjects or unable to abstain from alcohol from 24 hours prior to Screening visits and 24 hours prior to Period 2 Day (-1) until discharge at the end of Period 2.

    9. Female subjects who are pregnant or lactating. 10. Use of any prescription drugs within 14 days or 5 half-lives (whichever is longer) before the first dose of an investigational product, unless in the opinion of the investigator (or delegate) and the Sponsor's Medical Monitor the medication will not interfere with the study procedures, the pharmacokinetics of either the radiopharmaceutical or the investigational drug product, or compromise subject safety. An example of potentially acceptable drug use might be beta blockers in eye drops for glaucoma.

  • 11. Use of any non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) before the first dose of the study agents, unless in the opinion of the Investigator (or delegate) and the Sponsor's Medical Monitor the medication will not interfere with the study procedures, the pharmacokinetics of either the radiopharmaceutical or the investigational drug product, or compromise subject safety.
  • 12. Subjects who have received an investigational drug as part in another study within the last 30 days or 5 half-lives of the investigational drug for the previous study (whichever is longer).
  • 13. History of acquired immunodeficiency syndrome (AIDS).
  • 14. Poor peripheral venous access.
  • 15. Donation of ≥450 mL blood or loss of blood during surgery within 30 days prior to Day 1.
  • 16. Plasma donation >100 mL within 7 days prior to Day 1.
  • 17. In the Investigator's judgement it is better for the subject not to be enrolled in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04044781


Locations
Layout table for location information
United States, New York
Weill Cornell Medicine
New York, New York, United States, 10065
Sponsors and Collaborators
Tetra Discovery Partners
Investigators
Layout table for investigator information
Principal Investigator: Paul D Mozley, MD Weill Cornell College of Medicine
Layout table for additonal information
Responsible Party: Tetra Discovery Partners
ClinicalTrials.gov Identifier: NCT04044781    
Other Study ID Numbers: T2310-PET-102
First Posted: August 5, 2019    Key Record Dates
Last Update Posted: January 10, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No